Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GRWD5769 |
| Synonyms | |
| Therapy Description |
GRWD5769 inhibits ERAP1, which potentially induces anti-tumor immune activity (Cancer Res (2023) 83 (7_Supplement): 3467). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GRWD5769 | GRWD 5769|GRWD-5769 | GRWD5769 inhibits ERAP1, which potentially induces anti-tumor immune activity (Cancer Res (2023) 83 (7_Supplement): 3467). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06923761 | Phase Ib/II | Cemiplimab + GRWD5769 GRWD5769 | EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) (EMITT-1) | Recruiting | GBR | FRA | ESP | AUS | 0 |